CDC
CDC Health Advisory: Medetomidine emerges as a dangerous new fentanyl adulterant
On April, 2, 2026, CDC issued a Health Advisory warning that medetomidine, a non‑opioid α2‑adrenergic agonist approved for veterinary use, is rapidly replacing xylazine as a common adulterant in the U.S. illegal fentanyl supply. Its presence significantly increases the risk of overdose and is associated with a life‑threatening withdrawal syndrome distinct from typical opioid or xylazine withdrawal.
Reported effects of medetomidine intoxication are consistent with those of α2-agonists and include:
- marked bradycardia (heart rates as low as 32 beats per minute),
- hypotension, and
- profound, often prolonged sedation.
Unlike xylazine, medetomidine use does not seem to be associated with development of wounds.
Stopping medetomidine following regular use may lead to severe withdrawal, similar to clonidine withdrawal, with symptoms including hypertension, anxiety, nausea, vomiting, and fluctuating alertness, that can require emergency or intensive care.
Recommendations for clinicians:
- Maintain high suspicion for medetomidine exposure in patients presenting with fentanyl overdose or unusually severe withdrawal, especially when symptoms are resistant to typical management.
- Recognize limitations of naloxone: it reverses opioid effects but will not counteract medetomidine‑related sedation or bradycardia; repeated dosing may still be needed for opioid toxicity.
- Escalate care early for suspected medetomidine withdrawal; reported cases often required continuous IV dexmedetomidine to control autonomic symptoms.
- Avoid relying on routine urine drug screens, which do not detect medetomidine; clinical judgment is essential.
- Coordinate with public health and toxicology resources and consider reporting suspected cases to support surveillance.
- Educate patients who use drugs about the changing drug supply and heightened risks, and continue harm‑reduction strategies.
CDC emphasizes that shifts in the illicit drug supply can rapidly change clinical presentations. Early recognition and aggressive management may be lifesaving.